Robert Charles Breedlove serves as Principal Accounting Officer of Phathom Pharmaceuticals, Inc. (PHAT). Breedlove has reported 10 insider filings with the SEC since 2025. The most recent filing was in July 2026.
Every role Robert Charles Breedlove has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Phathom Pharmaceuticals, Inc. (PHAT)1 filingUpdated Aug 31, 2026
Robert Charles Breedlove is Principal Accounting Officer of Phathom Pharmaceuticals, Inc. (PHAT). 7 SEC Form 4 filings on record going back to 2025, most recently on 16 July 2026. Most recent open-market trade: sold $7K of PHAT on 5 November 2025. Lifetime open-market sales: $27K.
Every recent SEC Form 4 transaction Robert Charles Breedlove has reported, most recent first.
InsiderAlpha's records for Robert Charles Breedlove go back to 2025: 7 primary Form 4 filings, an average of 3.5 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Insiders who have reported open-market trades at the same companies as Robert Charles Breedlove. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Robert Charles Breedlove is a corporate insider, tracked as Principal Accounting Officer of Phathom Pharmaceuticals, Inc. (PHAT). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
1 primary Form 4 filing in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases and 3 open-market sales ($27K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$PHAT Phathom Pharmaceuticals, Inc.964 shares @ $12.56$12K